Baxter International Inc., the maker of blood products and intravenous drugs, sued Teva Pharmaceutical Industries Ltd. (TEVA) to enforce an indemnity agreement over claims the drugmakers sold the anesthetic propofol in a way that led some patients to develop hepatitis. Baxter contends in a Delaware Chancery Court lawsuit that an arbitration panel found Teva was bound by an agreement to cover all liability stemming from cases blaming tainted vials of propofol for colonoscopy patients developing hepatitis C. A Las Vegas jury last year ordered Teva and Baxter to pay more than $500 million in damages to a Las Vegas school principal on one such claim.
